DAPTOMYCIN FOR INJECTION POWDER FOR SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

DAPTOMYCIN

थमां उपलब्ध:

ACCORD HEALTHCARE INC

ए.टी.सी कोड:

J01XX09

INN (इंटरनेशनल नाम):

DAPTOMYCIN

डोज़:

500MG

फार्मास्यूटिकल फॉर्म:

POWDER FOR SOLUTION

रचना:

DAPTOMYCIN 500MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

15G/50G

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

CYCLIC LIPOPEPTIDES

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0152298001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2020-10-01

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DAPTOMYCIN FOR INJECTION
Lyophilized Powder for Solution, For Intravenous Use Only
500 mg/vial
Antibacterial Agent
Accord Healthcare Inc.
3535 boul. St-Charles, Suite 704
Kirkland, Quebec
H9H 5B9
Date of Revision:
August 31, 2020
Submission Control Number:
242602
_Page 2 of 60_
_Product Monograph of Daptomycin for Injection _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
19
DOSAGE AND ADMINISTRATION
.............................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 27
STORAGE AND STABILITY
.........................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 33
PART II: SCIENTIFIC INFORMATION
..............................................................................
34
PHARMACEUTICAL INFORMATION
.........................................................................
34
CLINICAL TRIALS
.........................................................................................................
35
DETA
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 31-08-2020

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें